Kronos Bio presents updated Phase 1/2 trial data for oral CDK9 inhibitor KB-0742 at ASCO 2024, showing manageable safety and tolerability.
Kronos Bio will present updated clinical data from its Phase 1/2 trial of KB-0742 at the 2024 ASCO Annual Meeting. The study, involving KB-0742, an oral inhibitor of CDK9 targeting MYC deregulation in solid tumors and non-Hodgkin lymphoma, demonstrates a manageable safety and tolerability profile. The company plans to enroll the dose escalation arm at the 80mg four-days-on, three-days-off schedule and will open the expansion cohort in Q3 2024.
May 23, 2024
4 Articles